Assignee
ZYNERBA PHARMACEUTICALS INC
US·12 granted patents·26 pending applications·180 citations·filing 2014–2024
Top patents by PatentIndex Score
38 records- 0197US9957246B2Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2016·Granted May 1, 2018·48 cites·12 claims
- 0295US11458110B2Treatment of Fragile X Syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2020·Granted Oct 4, 2022·4 cites·7 claims
- 0395US10758497B2Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Sep 1, 2020·14 cites·7 claims
- 0495US9533942B2Use of cannabidiol prodrugs in topical and transdermal administration with microneedlesZYNERBA PHARMACEUTICALS INC·Filed 2014·Granted Jan 3, 2017·39 cites·16 claims
- 0594US11779549B2Treatment of Fragile X Syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Granted Oct 10, 2023·2 cites·2 claims
- 0694US10568848B2Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Feb 25, 2020·13 cites·8 claims
- 0794US10471022B2Treatment of fragile X syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Nov 12, 2019·14 cites·6 claims
- 0894US10314792B2Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2018·Granted Jun 11, 2019·13 cites·7 claims
- 0994US10213390B1Treatment of fragile X syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2018·Granted Feb 26, 2019·19 cites·8 claims
- 1093US11458109B2Treatment of 22Q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Oct 4, 2022·7 cites·15 claims
- 1191US2025034104A1Prodrugs of tetrahydrocannabinol compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1289US2024217942A1Prodrugs of tetrahydrocannabinol compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1388US2024083866A1Prodrugs of tetrahydrocannabinol compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1484USRE47885EUse of cannabidiol prodrugs in pharmaceutical compositionsZYNERBA PHARMACEUTICALS INC·Filed 2018·Granted Mar 3, 2020·7 cites·18 claims
- 1582US2025213465A1Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1681US2022194916A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1779US2022096396A1Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1877US2024122873A1Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1977US2024148669A1Methods of treatment of osteoarthritis with transdermal cannabidiol gelZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2076US2021047284A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2176US2024189255A1Methods of treatment of osteoarthritis with transdermal cannabidiol gelZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2273US2020024248A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2373US2020247774A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2472US2020214995A1Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2572US2019233387A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2669US2018208572A1Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2769US2021077421A1Treatment of syngap1 encephalopathyZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2868US2021401769A1Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2967US2019083388A1Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3066US2021030665A1Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3165US2021369643A1Treatment of fragile x syndrome and autism spectrum disorder with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3262US9695143B2Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the sameZYNERBA PHARMACEUTICALS INC·Filed 2015·Granted Jul 4, 2017·0 cites·10 claims
- 3360US2023000792A1Treatment of 22q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3460US2020170963A1Methods of treatment of osteoarthritis with transdermal cannabidiol gelZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3559US2024342198A1Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidanceZYNERBA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3658US2023000793A1Treatment of 22q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3757US2024307418A1Treatment of sleep apnea with cbdZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3856US2024009210A1Cannabidiol for the Treatment of Refractory SeizuresZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ZYNERBA PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →